Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BridgeBio Pharma (BBIO) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to -$0.95.

  • BridgeBio Pharma's EPS (Basic) fell 1046.51% to -$0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2, marking a year-over-year decrease of 7427.39%. This contributed to the annual value of -$2.88 for FY2024, which is 2710.72% up from last year.
  • Latest data reveals that BridgeBio Pharma reported EPS (Basic) of -$0.95 as of Q3 2025, which was down 1046.51% from -$0.95 recorded in Q2 2025.
  • In the past 5 years, BridgeBio Pharma's EPS (Basic) ranged from a high of -$0.07 in Q2 2022 and a low of -$1.42 during Q4 2024
  • Moreover, its 5-year median value for EPS (Basic) was -$0.95 (2025), whereas its average is -$0.88.
  • Its EPS (Basic) has fluctuated over the past 5 years, first surged by 8939.39% in 2022, then crashed by 130000.0% in 2023.
  • Quarter analysis of 5 years shows BridgeBio Pharma's EPS (Basic) stood at -$1.02 in 2021, then grew by 9.76% to -$0.92 in 2022, then dropped by 4.35% to -$0.96 in 2023, then crashed by 48.38% to -$1.42 in 2024, then skyrocketed by 33.31% to -$0.95 in 2025.
  • Its EPS (Basic) was -$0.95 in Q3 2025, compared to -$0.95 in Q2 2025 and -$0.88 in Q1 2025.